The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome
Clinical trial NCT00570375 · WITHDRAWN
Trial details
- NCT number
- NCT00570375
- Sponsor
- University of Cincinnati
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-11-01
- Primary completion
- 2009-04-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.